A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA) in Patients With Relapsed or Refractory Solid Tumors

Trial Profile

A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA) in Patients With Relapsed or Refractory Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Birinapant (Primary) ; Pembrolizumab
  • Indications Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Mesothelioma; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Medivir AB; TetraLogic Pharmaceuticals
  • Most Recent Events

    • 09 Apr 2018 Planned number of patients changed from 104 to 135.
    • 04 Apr 2018 According to a Medivir AB media release, the company expects to complete the dose-escalation portion of this trial in 2018.
    • 29 Aug 2017 Planned End Date changed from 1 Mar 2021 to 1 Jun 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top